CompanyGraph
Zhejiang Haisen Pharmaceutical Co., Ltd.
001367 · SZSE · China
haisenpharma.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.56%
Annual Rate
CNY 0.12Paid annual
Payout Ratio
12.6%Sustainable
Last Ex-Dividend
May 13, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.13BCNY467.22M · vs all stocks (USD)
Trailing P/E
22.35xRevenue (TTM)
541.06MCNY80.71M · vs all stocks (USD)
Profit Margin
26.03%Beta
0.1550xvs all stocks
52-Week Change
-14.05%vs all stocks
Market Capitalization
3.13BCNY467.22M · vs all stocks (USD)
Enterprise Value
1.89BCNY282.19M · vs all stocks (USD)
Trailing P/E
22.35xPrice to Sales (TTM)
5.79xPrice to Book (MRQ)
1.95xEnterprise to Revenue
3.50xEnterprise to EBITDA
10.81xGross Margin
45.37%Profit Margin
26.03%Operating Margin
28.24%Return on Assets (TTM)
5.88%Return on Equity (TTM)
9.56%Revenue (TTM)
541.06MCNY80.71M · vs all stocks (USD)
Revenue per Share (TTM)
3.61CNYUpdated Sep 19, 2026Quarterly Revenue Growth
16.30%Gross Profit (TTM)
250.67MCNY37.39M · vs all stocks (USD)
EBITDA (TTM)
163.95MCNY24.46M · vs all stocks (USD)
Net Income (TTM)
140.82MCNY21.00M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
24.50%Operating Cash Flow (TTM)
178.59MCNY26.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
74.82MCNY11.16M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1160CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
0.56%vs all stocks
Payout Ratio
12.61%Revenue
532.26MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
289.55MCNYFY2025 · Dec 31, 2025Gross Profit
242.71MCNYFY2025 · Dec 31, 2025Operating Income
148.56MCNY22.16M · vs all stocks (USD)
Pre-tax Income
156.76MCNYFY2025 · Dec 31, 2025Income Tax Expense
20.88MCNYFY2025 · Dec 31, 2025Net Income
135.88MCNYFY2025 · Dec 31, 2025EBIT
157.10MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
182.42MCNYFY2025 · Dec 31, 2025Research & Development
38.86MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
25.51MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
346.05KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
135.88MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
118.87MCNYFY2025 · Dec 31, 2025Free Cash Flow
-33.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
900.01MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
135.88MCNYFY2025 · Dec 31, 2025Other Non-cash Items
866.02KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-16.48MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.39MCNYFY2025 · Dec 31, 2025Capital Expenditures
-152.26MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.09BCNYFY2025 · Dec 31, 2025Sale of Investments
1.94BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-297.25MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-17.45MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.86MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-15.59MCNYFY2025 · Dec 31, 2025Shares Outstanding
152.35MSharesUpdated Sep 19, 2026Float Shares
38.67MSharesUpdated Sep 19, 2026% Held by Insiders
78.21%vs all stocks
% Held by Institutions
0.37%vs all stocks
Total Cash (MRQ)
1.09BCNY162.31M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.42CNYUpdated Sep 19, 2026Total Debt (MRQ)
7.49MCNY1.12M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0048xCurrent Ratio (MRQ)
13.39xBook Value per Share (MRQ)
10.55CNYUpdated Sep 19, 2026Total Assets
1.63BCNY243.17M · vs all stocks (USD)
Total Current Assets
1.28BCNYFY2025 · Dec 31, 2025Total Liabilities
136.48MCNYFY2025 · Dec 31, 2025Total Non-current Assets
349.42MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
20.18MCNYFY2025 · Dec 31, 2025Total Current Liabilities
116.30MCNYFY2025 · Dec 31, 2025Cash
909.33MCNYFY2025 · Dec 31, 2025Cash Equivalents
153.85KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
909.49MCNYFY2025 · Dec 31, 2025Other Short-term Investments
151.69MCNYFY2025 · Dec 31, 2025Accounts Receivable
86.30MCNYFY2025 · Dec 31, 2025Inventory
108.47MCNYFY2025 · Dec 31, 2025Accounts Payable
44.88MCNYFY2025 · Dec 31, 2025Short-term Debt
1.33MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.99MCNYFY2025 · Dec 31, 2025Long-term Debt
6.10MCNYFY2025 · Dec 31, 2025Common Stock (Book)
152.35MCNYFY2025 · Dec 31, 2025Retained Earnings
555.36MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.49BCNY222.81M · vs all stocks (USD)
Treasury Stock
18.86MCNYFY2025 · Dec 31, 202552-Week Low
16.78CNYUpdated Sep 19, 202652-Week High
28.00CNYUpdated Sep 19, 202652-Week Change
-14.05%vs all stocks
Beta
0.1550xvs all stocks
50-Day MA
19.31CNYUpdated Sep 19, 2026200-Day MA
21.95CNYUpdated Sep 19, 2026Avg 10-Day Volume
1.29MSharesUpdated Sep 19, 2026Avg 30-Day Volume
2.67MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.9200CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Jiaoda Onlly Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jenscare Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule